

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Jacobson Pharma Corporation Limited**

**雅各臣科研製藥有限公司**

(Incorporated under the laws of the Cayman Islands with limited liability)

Stock Code : 2633

### **VOLUNTARY ANNOUNCEMENT**

### **POTENTIAL SPIN-OFF LISTING OF BRANDED HEALTHCARE BUSINESS**

This announcement is made by Jacobson Pharma Corporation Limited (stock code: 2633) (the “**Company**”) on a voluntary basis.

The Company proposes to spin-off and seek a separate listing of its branded healthcare business (the “**Potential Spin-off Listing**”) on the main board of The Hong Kong Stock Exchange Limited (the “**Stock Exchange**”). For purpose of pursuing the Potential Spin-off Listing, the board of directors of the Company (the “**Board**”) has approved the engagement of relevant professional parties, and a corporate reorganization to reorganize relevant group companies engaging in the branded healthcare business under a holding company (“**Newco**”) that will serve as the listing vehicle for the Potential Spin-off Listing. A spin-off proposal under Practice Note 15 of The Rules Governing the Listing of Securities of the Stock Exchange (the “**Listing Rules**”) will be submitted to the Stock Exchange in due course.

The branded healthcare business to be spun-off is expected to comprise proprietary medicines, proprietary Chinese medicines and branded health and wellness products such as health supplements, personal care products and diagnostic kits. The Potential Spin-off Listing is expected to facilitate the expansion of the branded healthcare business under a separate platform from the generic drug business of the Company and such segregation of business segments is considered to be in line with the development strategies of the Company.

Under the transaction structure of the Potential Spin-off Listing as currently contemplated, Newco is expected to remain as a subsidiary of the Company after the Potential Spin-off Listing. However, the detailed terms of the Potential Spin-off Listing are subject to further determination by the Company and the final decision of the Board, taking into account factors, among others, prevailing market conditions. Upon determination of the implications of the Potential Spin-off Listing and the relevant percentage ratios under the Listing Rules, the Company will make further announcement(s) where applicable in compliance with the Listing Rules.

**The Potential Spin-off Listing is at a preliminary stage and its terms are subject to determination by the Company and the final decision of the Board. The Potential Spin-off Listing is also subject to among others, the approval of the spin-off proposal under Practice Note 15 of the Listing Rules and the listing approval by the Stock Exchange. Shareholders and other investors of the Company should be aware that there is no assurance that the Potential Spin-off Listing will be proceeded with and it may or may not materialize. Shareholders and investors are advised to exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Jacobson Pharma Corporation Limited**  
**Yim Chun Leung**  
*Executive Director and Company Secretary*

Hong Kong, 20 January 2020

*As at the date of this announcement, the Board comprises Mr. Sum Kwong Yip, Derek (also as Chairman and Chief Executive Officer), Mr. Yim Chun Leung (also as Company Secretary) and Ms. Pun Yue Wai as executive Directors, Professor Lam Sing Kwong, Simon as non-executive Director, and Dr. Lam Kwing Tong, Alan, Mr. Young Chun Man, Kenneth and Professor Wong Chi Kei, Ian as independent non-executive Directors.*